横浜市立大学　内分泌・糖尿病内科

2018-2023主要論文

2023年

  1. Endocrinological evaluation of dawn phenomenon in patients with diabetes and comparison of insulin glargine U-100 biosimilar (Insulin Glargine BS Injection “Lilly”) and glargine U-300 (Lantus XR): a randomized controlled study. Hasebe M, Satoh S, Ito K, Tamura H, Terauchi Y. Endocr J. 2023 May 11. doi: 10.1507/endocrj.EJ22-0562. Online ahead of print. PMID: 37164694
  2. A disproportionality analysis of the adverse effect profiles of methimazole and propylthiouracil in patients with hyperthyroidism using the Japanese Adverse Drug Event Report Database. Arai M, Tsuno T, Konishi H, Nishiyama K, Terauchi Y, Inoue R, Shirakawa J. Thyroid. 2023 May 2. doi: 10.1089/thy.2023.0030. Online ahead of print. PMID: 37130038
  3. Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Iijima T, Shibuya M, Ito Y, Terauchi Y. J Diabetes Investig. 2023 Mar 5. doi: 10.1111/jdi.14000. Online ahead of print. PMID: 36871272 Free article.
  4. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study. Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y. Diabetes Ther. 2023 Apr;14(4):671-689. doi: 10.1007/s13300-023-01373-w. Epub 2023 Feb 21. PMID: 36809494 Free PMC article.
  5. Sleep duration and food intake in people with type 2 diabetes mellitus and factors affecting confectionery intake. Akiyama T, Yamakawa T, Orime K, Suzuki J, Sakamoto R, Matsuura-Shinoda M, Shigematsu E, Takahashi K, Kaneshiro M, Asakura T, Tanaka S, Kawata T, Yamada Y, Isozaki T, Takahashi A, Osada UN, Kadonosono K, Terauchi Y. J Diabetes Investig. 2023 Feb 6. doi: 10.1111/jdi.13987. Online ahead of print. PMID: 36747481 Free article.
  6. Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study. Ito K, Satoh S, Kondo Y, Tamura H, Hasebe M, Terauchi Y. Diabetol Int. 2022 Jul 13;14(1):51-57. doi: 10.1007/s13340-022-00592-z. eCollection 2023 Jan. PMID: 36636162
  7. Protective effects of S100A8 on sepsis mortality: Links to sepsis risk in obesity and diabetes. Miyashita D, Inoue R, Tsuno T, Okuyama T, Kyohara M, Nakahashi-Oda C, Nishiyama K, Fukushima S, Inada Y, Togashi Y, Shibuya A, Terauchi Y, Shirakawa J. iScience. 2022 Nov 23;25(12):105662. doi: 10.1016/j.isci.2022.105662. eCollection 2022 Dec 22. PMID: 36505926 Free PMC article.

2022年

  1. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study. Matsuhisa M, Miyoshi H, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y. Diabetes Ther. 2023 Jan;14(1):219-236. doi: 10.1007/s13300-022-01333-w. Epub 2022 Nov 23. PMID: 36422802 Free PMC article.
  2. Association between circulating SerpinB1 levels and insulin sensitivity in Japanese with type 2 diabetes: A single-center, cross-sectional, observational study. Kyohara M, Miyashita D, Inoue R, Nishiyama K, Tsuno T, Okuyama T, Togashi Y, Terauchi Y, Shirakawa J. PLoS One. 2022 Nov 4;17(11):e0276915. doi: 10.1371/journal.pone.0276915. eCollection 2022. PMID: 36331940 Free PMC article.
  3. Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan. Kubota S, Haraguchi T, Kuwata H, Seino Y, Murotani K, Tajima T, Terashima G, Kaneko M, Takahashi Y, Takao K, Kato T, Shide K, Imai S, Suzuki A, Terauchi Y, Yamada Y, Seino Y, Yabe D. J Diabetes Investig. 2023 Jan;14(1):67-74. doi: 10.1111/jdi.13921. Epub 2022 Oct 25.PMID: 36281720 Free PMC article.
  4. The METRO study: a retrospective analysis of the efficacy of metformin for type 2 diabetes in Japan. Harada M, Kondo Y, Sugiyama M, Ohira A, Ichikawa M, Akiyama T, Orime K, Takai T, Yamakawa T, Terauchi Y. Endocr J. 2023 Jan 30;70(1):121-128. doi: 10.1507/endocrj.EJ22-0330. Epub 2022 Oct 18. PMID: 36261368 Free article.
  5. Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL). Kaneto H, Baxter M, Takahashi Y, Terauchi Y. Adv Ther. 2022 Dec;39(12):5453-5473. doi: 10.1007/s12325-022-02311-1. Epub 2022 Oct 7. PMID: 36207508 Free PMC article.
  6. E2F1 transcription factor mediates a link between fat and islets to promote β cell proliferation in response to acute insulin resistance. Shirakawa J, Togashi Y, Basile G, Okuyama T, Inoue R, Fernandez M, Kyohara M, De Jesus DF, Goto N, Zhang W, Tsuno T, Kin T, Pan H, Dreyfuss JM, Shapiro AMJ, Yi P, Terauchi Y, Kulkarni RN. Cell Rep. 2022 Oct 4;41(1):111436. doi: 10.1016/j.celrep.2022.111436. PMID: 36198264 Free PMC article.
  7. Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Sato K, Terauchi Y, Tamura K, Kanamori A. Sci Rep. 2022 Sep 27;12(1):16106. doi: 10.1038/s41598-022-20313-5. PMID: 36167964 Free PMC article.
  8. Association of continuous positive airway pressure therapy on cardiac hypertrophy in patients with sleep apnea comorbid with type 2 diabetes mellitus. Ohira A, Yamakawa T, Iwahashi N, Tanaka S, Sugiyama M, Harada M, Ichikawa M, Akiyama T, Orime K, Terauchi Y. Endocr J. 2023 Jan 30;70(1):47-58. doi: 10.1507/endocrj.EJ22-0308. Epub 2022 Sep 10. PMID: 36089339 Free article.
  9. Abdominal aortic calcification is associated with Fibrosis-4 index and low body mass index in type 2 diabetes patients: A retrospective cross-sectional study. Togashi Y, Miyashita D, Tsuno T, Inoue R, Okuyama T, Kyohara M, Nishiyama K, Arai M, Kanematsu K, Kanataki S, Terauchi Y, Shirakawa J. J Diabetes Investig. 2022 Nov;13(11):1861-1872. doi: 10.1111/jdi.13883. Epub 2022 Jul 23. PMID: 35818826 Free PMC article.
  10. Uncoupling protein 2 and aldolase B impact insulin release by modulating mitochondrial function and Ca2+ release from the ER. Inoue R, Tsuno T, Togashi Y, Okuyama T, Sato A, Nishiyama K, Kyohara M, Li J, Fukushima S, Kin T, Miyashita D, Shiba Y, Atobe Y, Kiyonari H, Bando K, Shapiro AMJ, Funakoshi K, Kulkarni RN, Terauchi Y, Shirakawa J. iScience. 2022 Jun 14;25(7):104603. doi: 0.1016/j.isci.2022.104603. eCollection 2022 Jul 15. PMID: 35800776 Free PMC article.
  11. Diagnostic accuracy of home sleep apnea testing using peripheral arterial tonometry for sleep apnea: A systematic review and meta-analysis. Ichikawa M, Akiyama T, Tsujimoto Y, Anan K, Yamakawa T, Terauchi Y. J Sleep Res. 2022 Dec;31(6):e13682. doi: 10.1111/jsr.13682. Epub 2022 Jul 6. PMID: 35793907
  12. Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes. Yamazaki S, Takano T, Tachibana K, Takeda S, Terauchi Y. Diabetes Ther. 2022 Aug;13(8):1559-1569. doi: 10.1007/s13300-022-01292-2. Epub 2022 Jul 6. PMID: 35793047 Free PMC article.
  13. Corrigendum to ‘Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry’ [Journal of Cardiology 72 (2018) 300-306]. Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Akishita M, Hasebe N, Kario K, Mizokami Y, Nagata K, Nakamura M, Terauchi Y, Yamamoto T, Teramukai S, Kimura T, Kaburagi J, Takita A. J Cardiol. 2022 Oct;80(4):375-376. doi: 10.1016/j.jjcc.2022.06.008. Epub 2022 Jun 30. PMID: 35779981 No abstract available.
  14. Comparing the course and delivery outcomes of Japanese twin pregnancies with and without gestational diabetes mellitus: a single-center retrospective analysis. Sugiyama M, Yamakawa T, Harada M, Ohira A, Ichikawa M, Akiyama T, Orime K, Nakanishi S, Aoki S, Terauchi Y. Endocr J. 2022 Oct 28;69(10):1183-1191. doi: 10.1507/endocrj.EJ21-0537. Epub 2022 Jul 16. PMID: 35705298 Free article.
  15. Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function. Yamauchi Y, Nakamura A, Yokota T, Takahashi K, Kawata S, Tsuchida K, Omori K, Nomoto H, Kameda H, Cho KY, Anzai T, Tanaka S, Terauchi Y, Miyoshi H, Atsumi T. Sci Rep. 2022 Jun 13;12(1):9740. doi: 10.1038/s41598-022-13888-6. PMID: 35697838 Free PMC article.
  16. Recurrent Subacute Thyroiditis in a Patient With Human Leukocyte Antigen-associated Predisposition to Graves Disease. Yamakawa T, Sakakibara T, Terauchi Y. AACE Clin Case Rep. 2021 Dec 16;8(3):113-115. doi: 10.1016/j.aace.2021.12.001. eCollection 2022 May-Jun. PMID: 35602878 Free PMC article.
  17. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study. Terauchi Y, Usami M, Inoue T. Adv Ther. 2022 Jun;39(6):2873-2888. doi: 10.1007/s12325-022-02121-5. Epub 2022 Apr 21. PMID: 35449321 Free PMC article.
  18. A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg. Seino Y, Miyoshi H, Bosch Traberg H, Divyalasya TVS, Nishijima K, Terauchi Y. J Diabetes Investig. 2022 Aug;13(8):1321-1329. doi: 10.1111/jdi.13789. Epub 2022 Apr 8. PMID: 35285173 Free PMC article. Clinical Trial.
  19. Efficacy of education on injection technique for patients diagnosed with diabetes with lipohypertrophy: systematic review and meta-analysis. Ichikawa M, Akiyama T, Tsujimoto Y, Anan K, Yamakawa T, Terauchi Y. BMJ Open. 2022 Mar 7;12(3):e055529. doi: 10.1136/bmjopen-2021-055529. PMID: 35256444 Free PMC article.
  20. Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study. Tamura H, Kondo Y, Ito K, Hasebe M, Satoh S, Terauchi Y. PLoS One. 2022 Feb 16;17(2):e0262831. doi: 10.1371/journal.pone.0262831. eCollection 2022. PMID: 35171918 Free PMC article. Clinical Trial.
  21. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, Kimura M, Saito N, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Machimura H, Hishiki T, Umezawa S, Shimura H, Nakajima S, Yamamoto H, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Diabetes Res Clin Pract. 2022 Mar;185:109231. doi: 10.1016/j.diabres.2022.109231. Epub 2022 Feb 5. PMID: 35131376
  22. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials. Yabe D, Deenadayalan S, Horio H, Kaneto H, Jensen TB, Terauchi Y, Yamada Y, Inagaki N. J Diabetes Investig. 2022 Jun;13(6):975-985. doi: 10.1111/jdi.13764. Epub 2022 Mar 3. PMID: 35112504 Free PMC article. Clinical Trial.
  23. A randomized controlled trial of a structured program combining aerobic and resistance exercise for adults with type 2 diabetes in Japan. Terauchi Y, Takada T, Yoshida S. Diabetol Int. 2021 Apr 28;13(1):75-84. doi: 10.1007/s13340-021-00506-5. eCollection 2022 Jan. PMID: 35059244 Free PMC article.
  24. A cross-sectional study of the relationship between quality of life and sleep quality in Japanese patients with type 1 diabetes mellitus. Ichikawa M, Yamakawa T, Sakamoto R, Takahashi K, Suzuki J, Matsuura-Shinoda M, Shigematsu E, Tanaka S, Kaneshiro M, Asakura T, Kawata T, Yamada Y, Nezu Osada U, Isozaki T, Takahashi A, Kadonosono K, Terauchi Y. Endocr J. 2022 Apr 28;69(4):399-406. doi: 10.1507/endocrj.EJ21-0408. Epub 2021 Nov 30. PMID: 34853196 Free article

2021年

  1. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.Araki E, Terauchi Y, Watada H, Deenadayalan S, Christiansen E, Horio H, Kadowaki T.Diabetes Obes Metab. 2021 Dec;23(12):2785-2794. doi: 10.1111/dom.14536. Epub 2021 Sep 27.PMID: 34472698
  2.  Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.Matsuba I, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Kanamori A.Diabetes Obes Metab. 2021 Dec;23(12):2614-2622. doi: 10.1111/dom.14508. Epub 2021 Aug 12.PMID: 34338409
  3.  Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study.Terui S, Akamatsu R, Arai M, Inoue R, Okuyama T, Kyohara M, Li J, Tsuno T, Miyashita D, Togashi Y, Terauchi Y, Shirakawa J.Diabetes Ther. 2021 Nov;12(11):2873-2889. doi: 10.1007/s13300-021-01147-2. Epub 2021 Sep 17.PMID: 34533697
  4. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.Minami T, Kameda A, Terauchi Y.Expert Opin Pharmacother. 2021 Nov;22(16):2087-2094. doi: 10.1080/14656566.2021.1939675. Epub 2021 Jun 11.PMID: 34114925 Review.
  5.  Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.Nishimiya N, Tajima K, Imajo K, Kameda A, Yoshida E, Togashi Y, Aoki K, Inoue T, Nakajima A, Utsunomiya D, Terauchi Y.Intern Med. 2021 Nov 1;60(21):3391-3399. doi: 10.2169/internalmedicine.7134-21. Epub 2021 May 14.PMID: 33994437 Free article.
  6. Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice.Kawata S, Nakamura A, Miyoshi H, Yang K, Shigesawa I, Yamauchi Y, Tsuchida K, Omori K, Takahashi K, Nomoto H, Kameda H, Cho KY, Terauchi Y, Atsumi T.Diabetes Obes Metab. 2021 Oct 27. doi: 10.1111/dom.14586. Online ahead of print.PMID: 34704329
  7.  Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?Nakamura A, Omori K, Terauchi Y.Diabetes Obes Metab. 2021 Oct;23(10):2199-2206. doi: 10.1111/dom.14459. Epub 2021 Jun 22.PMID: 34105236 Review.
  8.  Imeglimin ameliorates β-cell apoptosis by modulating the endoplasmic reticulum homeostasis pathway.Li J, Inoue R, Togashi Y, Okuyama T, Satoh A, Kyohara M, Nishiyama K, Tsuno T, Miyashita D, Kin T, Shapiro AMJ, Chew RSE, Keong Teo AK, Oyadomari S, Terauchi Y, Shirakawa J.Diabetes. 2021 Sep 29:db210123. doi: 10.2337/db21-0123. Online ahead of print.PMID: 34588186
  9.  Validity and reliability of the Japanese version of the diabetes knowledge test among in-patients with type 2 diabetes.Minami T, Shirakawa J, Hiiragi H, Yamada T, Suzuki Y, Shirabe S, Maeda H, Terauchi Y.J Diabetes Investig. 2021 Sep 26. doi: 10.1111/jdi.13683. Online ahead of print.PMID: 34564953 Free article.
  10.  Glucokinase is required for high-starch diet-induced β-cell mass expansion in mice.Tsuchida K, Nakamura A, Miyoshi H, Yang K, Yamauchi Y, Kawata S, Omori K, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Seino Y, Terauchi Y, Atsumi T.J Diabetes Investig. 2021 Sep;12(9):1545-1554. doi: 10.1111/jdi.13532. Epub 2021 Mar 30.PMID: 33638884 Free PMC article.
  11. Impaired insulin secretion and related factors in East Asian individuals.Nakamura A, Terauchi Y.J Diabetes Investig. 2021 Aug 28. doi: 10.1111/jdi.13650. Online ahead of print.PMID: 34453417 Free article. No abstract available.
  12. Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial.Kawai Y, Sankoda A, Waki K, Miyake K, Hayashi A, Mieno M, Wakui H, Tsurutani Y, Saito J, Hirawa N, Yamakawa T, Komiya S, Isogawa A, Satoh S, Minami T, Osada U, Iwamoto T, Takano T, Terauchi Y, Tamura K, Yamauchi T, Kadowaki T, Nangaku M, Kashihara N, Ohe K.JMIR Res Protoc. 2021 Aug 17;10(8):e31061. doi: 10.2196/31061.PMID: 34402802 Free PMC article.
  13. Associations of impaired glucose tolerance and sleep disorders with mortality among the US general population.Inoue K, Semba E, Yamakawa T, Terauchi Y.BMJ Open Diabetes Res Care. 2021 Aug;9(1):e002047. doi: 10.1136/bmjdrc-2020-002047.PMID: 34353879 Free PMC article.
  14. Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes.Harada M, Yamakawa T, Kashiwagi R, Ohira A, Sugiyama M, Sugiura Y, Kondo Y, Terauchi Y.PLoS One. 2021 Jul 22;16(7):e0255147. doi: 10.1371/journal.pone.0255147. eCollection 2021.PMID: 34293055 Free PMC article.
  15.  Asymptomatic meningitis diagnosed by positron emission tomography in a patient with syndrome of inappropriate antidiuretic hormone secretion: a case report.Hasebe M, Shirakawa J, Miyashita D, Kunishita R, Kyohara M, Okuyama T, Togashi Y, Terauchi Y.J Med Case Rep. 2021 Jul 22;15(1):390. doi: 10.1186/s13256-021-02956-6.PMID: 34289912 Free PMC article.
  16.  The Roles of the IGF Axis in the Regulation of the Metabolism: Interaction and Difference between Insulin Receptor Signaling and IGF-I Receptor Signaling.Okuyama T, Kyohara M, Terauchi Y, Shirakawa J.Int J Mol Sci. 2021 Jun 24;22(13):6817. doi: 10.3390/ijms22136817.PMID: 34202916 Free PMC article. Review.
  17.  The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes.Inoue R, Nishiyama K, Li J, Miyashita D, Ono M, Terauchi Y, Shirakawa J.Cells. 2021 Jun 24;10(7):1589. doi: 10.3390/cells10071589.PMID: 34202521 Free PMC article. Review.\
  18.  Are current SGLT2 Inhibitors efficacious treatment options for Type 1 diabetes?Koike Y, Terauchi Y.Expert Opin Pharmacother. 2021 Jun;22(9):1079-1081. doi: 10.1080/14656566.2021.1900824. Epub 2021 Mar 23.PMID: 33754937 No abstract available.\
  19. Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β-Cell Mass in db/db Mice.Omori K, Nakamura A, Miyoshi H, Yamauchi Y, Kawata S, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Terauchi Y, Atsumi T.Diabetes. 2021 Apr;70(4):917-931. doi: 10.2337/db20-0881. Epub 2021 Feb 18.PMID: 33608422 Free article.\
  20. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.Okuyama T, Shirakawa J, Nakamura T, Murase T, Miyashita D, Inoue R, Kyohara M, Togashi Y, Terauchi Y.Sci Rep. 2021 Feb 12;11(1):3768. doi: 10.1038/s41598-021-83234-9.PMID: 33580173 Free PMC article.
  21. Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study).Hirose T, Odawara M, Matsuhisa M, Koshida R, Senda M, Tanaka Y, Terauchi Y.Diabetes Res Clin Pract. 2021 Feb;172:108647. doi: 10.1016/j.diabres.2020.108647. Epub 2020 Dec 24.PMID: 33359753 Free article
  22.  Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study).Matsuhisa M, Odawara M, Hirose T, Koshida R, Senda M, Tanaka Y, Terauchi Y.Expert Opin Pharmacother. 2021 Feb;22(2):249-256. doi: 10.1080/14656566.2020.1810665. Epub 2020 Aug 25.PMID: 32840155
  23.  Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, Yasuda G, Yoshii T, Haruhara K, Kobayashi Y, Yamanaka T, Terauchi Y, Tamura K.Sci Rep. 2021 Jan 13;11(1):951. doi: 10.1038/s41598-020-79687-z.PMID: 33441623 Free PMC article.

2020年

  1. Shirakawa J, Terauchi Y. Potential linkage between DPP-4 inhibitor use and the risk of pancreatitis/pancreatic cancer. J Diabetes Investig. 2019 Nov 27. doi: 10.1111/jdi.13192. [Epub ahead of print] PubMed PMID: 31774618.
  2. Shirakawa J, Terauchi Y. Newer perspective on the coupling between glucose-mediated signaling and β-cell functionality. Endocr J. 2019 Nov 6. doi: 10.1507/endocrj.EJ19-0335. [Epub ahead of print] PubMed PMID: 31694991.
  3. Shirakawa J, Tajima K, Okuyama T, Kyohara M, Togashi Y, De Jesus DF, Basile G, Kin T, Shapiro AMJ, Kulkarni RN, Terauchi Y. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 2020 Mar;63(3):577-587.
  4. Miya A, Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study Health Study. J Diabetes Investig. 2020 Jan 30;11(4):964-70.
  5. Matsuba I, Kanamori A, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Tanaka Y. Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study. Diabetes Technol Ther. 2020 Mar;22(3):228-234. doi: 10.1089/dia.2019.0372. Epub 2020
  6. Iijima T, Aoki K, Kondo Y, Terauchi Y. Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial. J Clin Med Res. 2020 Feb;12(2):73-78. doi: 10.14740/jocmr4084. Epub 2020 Feb 1.
  7. Orime K, Terauchi Y. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2020 Sep 29:
  8. Matsuhisa M, Odawara M, Hirose T, Koshida R, Senda M, Tanaka Y, Terauchi Y. Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study). Expert Opin Pharmacother. 2020 Aug 25:1-8. doi: 10.1080/14656566.2020.1810665.
  9. Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M, Ito S, Kaneshiro M, Kanamori A, Kubota A, Shinoda K, Takai M, Takuma T, Takihata M, Takeda H, Tanaka K, Matsuzawa Y, Machimura H, Minagawa F, Minami N, Mokubo A, Miyakawa M, Terauchi Y, Tanaka Y. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study. J Diabetes Investig. 2020 Mar 9;11(5):1248-57. doi: 10.1111/jdi.13248.
  10. Iwata W, Unoki-Kubota H, Kato H, Shimizu A, Matsumoto M, Imasawa T, Igarashi A, Matsumoto K, Noda T, Terauchi Y, Nangaku M, Kasuga M, Kaburagi Y. Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure. PLoS One. 2020 Mar 19;15(3):e0229397.
  11. Nakaguchi H, Kondo Y, Kyohara M, Konishi H, Oiwa K, Terauchi Y. Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study. J Diabetes Investig. 2020 Apr 11. doi: 10.1111/jdi.13270.
  12. Terauchi Y, Nakama T, Spranger R, Amano A, Inoue T, Niemoeller E. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The LixiLan JP-O2 Randomized Clinical Trial. Diabetes Obes Metab. 2020 Apr 14. doi: 10.1111/dom.14036.
  13. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Inverse correlation between serum high-molecular-weight adiponectin and proinsulin level in a Japanese population: The Dynamics of Lifestyle and Neighborhood Community on Health Study. J Diabetes Investig. 2020 Jun 12. doi: 10.1111/jdi.13323.
  14. Aoki K, Kamiyama H, Takihata M, Taguri M, Shibata E, Shinoda K, Yoshii T, Nakajima S, Terauchi Y. Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study. Endocr J. 2020 Sep 28;67(9):957-962.
  15. Odawara M, Matsuhisa M, Hirose T, Koshida R, Senda M, Tanaka Y, Terauchi Y. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). Expert Opin Pharmacother. 2020 Jul 22:1-10. doi: 10.1080/14656566.2020.1785430.
  16. Yamamoto S, Hachiya Y, Yuasa E, Takeuchi A, Ishidao T, Mihara M, Terauchi Y, Ichiba M, Hori H. Evaluation of the ceiling levels of ortho-phthalaldehyde exposure among health care workers engaged in endoscope disinfection: A new methodology using video-exposure monitoring. J Occup Health. 2020 Jan;62(1):e12139.
  17. Wang H, Mizuno K, Takahashi N, Kobayashi E, Shirakawa J, Terauchi Y, Kasai H, Okunishi K, Izumi T. Melanophilin Accelerates Insulin Granule Fusion Without Predocking to the Plasma Membrane. Diabetes. 2020 Sep 29:db200069. doi: 10.2337/db20-0069.
  18. Kyohara M, Shirakawa J, Okuyama T, Togashi Y, Inoue R, Li J, Miyashita D, Terauchi Y. Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects. Diabetol Metab Syndr. 2020 Sep 29;12:83. doi: 10.1186/s13098-020-00591-7.

2019年

  1. Yamakawa T, Sakamoto R, Takahashi K, Suzuki J, Matuura-Shinoda M, Takahashi M, Shigematsu E, Tanaka S, Kaneshiro M, Asakura T, Kawata T, Yamada Y, Osada UN, Isozaki T, Takahashi A, Kadonosono K, Terauchi Y. Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study. J Diabetes Investig. 2018 Aug 1. doi: 10.1111/jdi.12903. [Epub ahead of print] PubMed PMID: 30070047.
  2. Yamamoto M, Terauchi Y, Sakuda A, Takahashi M. Binder-free sheet-type all-solid-state batteries with enhanced rate capabilities and high energy densities. Sci Rep. 2018 Jan 19;8(1):1212.
  3.  Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators. Achieving LDL cholesterol target levels <1.81 mmol/L may provide
    extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with
    Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13575. [Epub ahead of print] PubMed PMID: 30393955.
  4.  Terauchi Y, Ozaki A, Zhao X, Teoh C, Jaffe D, Tajima Y, Shuto Y. Humanistic and economic burden of cardiovascular disease related comorbidities and hypoglycaemia among patients with type 2 diabetes in Japan. Diabetes Res Clin Pract. 2019 Jan 24. pii: S0168-8227(18)31334-2. doi: 10.1016/j.diabres.2019.01.019. [Epub ahead of print] PubMed PMID: 30685348.
  5.  Koike Y, Shirabe SI, Maeda H, Yoshimoto A, Arai K, Kumakura A, Hirao K, Terauchi Y. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019 Feb 1. pii: S0168-8227(18)31513-4. doi: 10.1016/j.diabres.2019.01.029. [Epub ahead of print] PubMed PMID: 30716347.
  6. Shinoda M, Yamakawa T, Takahashi K, Nagakura J, Suzuki J, Sakamoto R, Kadonosono K, Terauchi Y. PREVALENCE OF OBSTRUCTIVE SLEEP APNEA DETERMINED BY THE WATCHPAT IN NONOBESE JAPANESE PATIENTS WITH POOR GLUCOSE CONTROL AND TYPE 2 DIABETES. Endocr Pract. 2019 Feb;25(2):170-177. doi: 10.4158/EP-2018-0200. PubMed
    PMID: 30817196.
  7. Terauchi Y, Utsunomiya K, Yasui A, Seki T, Cheng G, Shiki K, Lee J. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. Diabetes Ther. 2019 Jun;10(3):951-963. doi: 10.1007/s13300-019-0604-8. Epub 2019 Mar 25. PubMed PMID: 30912033; PubMed Central PMCID: PMC6531579.
  8. Konishi H, Shirakawa J, Arai M, Terauchi Y. Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes. Endocr J. 2019 Jun 28;66(6):571-574. doi: 10.1507/endocrj.EJ18-0553. Epub 2019 Apr 2. PubMed PMID: 30944270.
  9. Aoki K, Sato H, Terauchi Y. Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones. Endocr J. 2019 May 28;66(5):395-401. doi: 10.1507/endocrj.EJ19-0041. Epub 2019 Apr 23. PubMed PMID: 31019154.
  10. Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A,
    Motomiya T, Waseda M, Miyakawa M, Terauchi Y, Tanaka Y, Matsuba I. Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study. J Clin Med Res. 2019 May;11(5):311-320. doi: 10.14740/jocmr3677. Epub 2019 Apr 14. PubMed PMID:
    31019624; PubMed Central PMCID: PMC6469892.
  11. Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. J Diabetes Investig. 2019 Nov;10(6):1518-1526. doi: 10.1111/jdi.13066. Epub 2019 May 28. PubMed PMID: 31033218; PubMed Central PMCID: PMC6825952.
  12. Goto A, Takao T, Yoshida Y, Kawazu S, Iwamoto Y, Terauchi Y. Causes of death and estimated life expectancy among people with diabetes: A retrospective cohort study in a diabetes clinic. J Diabetes Investig. 2019 May 21. doi: 10.1111/jdi.13077. [Epub ahead of print] PubMed PMID: 31111637.
  13. Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzík M; PIONEER 1 Investigators. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019 Sep;42(9):1724-1732. doi: 10.2337/dc19-0749. Epub 2019 Jun 11. PubMed PMID: 31186300.
  14. Omori K, Nakamura A, Miyoshi H, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Takagi R, Hatanaka KC, Terauchi Y, Atsumi T. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. Metabolism. 2019 Sep;98:27-36. doi: 10.1016/j.metabol.2019.06.006. Epub 2019 Jun 14. PubMed PMID: 31202833.
  15. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Proinsulin is sensitive to reflect glucose intolerance. J Diabetes Investig. 2019 Jun 21. doi: 10.1111/jdi.13106. [Epub ahead of print] PubMed PMID: 31222973.
  16. Suzuki J, Yamakawa T, Oba M, Nagakura J, Shigematsu E, Tamura H, Takahashi K, Okamoto Y, Sakamoto R, Shinoda M, Takano T, Kadonosono K, Terauchi Y. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an
    open-label, randomized controlled study. Endocr J. 2019 Nov 28;66(11):971-982. doi: 10.1507/endocrj.EJ18-0309. Epub 2019 Jul 4. PubMed PMID: 31270291.
  17. Miyazaki T, Shirakawa J, Nagakura J, Shibuya M, Kyohara M, Okuyama T, Togashi Y, Nakamura A, Kondo Y, Satoh S, Nakajima S, Taguri M, Terauchi Y. Influence of Timing of Insulin Initiation on Long-term Glycemic Control in Japanese Patients with Type 2 Diabetes: A Retrospective Cohort Study. Intern Med. 2019 Dec
    1;58(23):3361-3367. doi: 10.2169/internalmedicine.3060-19. Epub 2019 Jul 22. PubMed PMID: 31327835.
  18. Takihata M, Terauchi Y. The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. Expert Opin Pharmacother. 2019 Dec;20(17):2185-2194. doi: 10.1080/14656566.2019.1656717. Epub 2019 Aug 26. PubMed PMID: 31450983.
  19. Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, Aoki K, Yasuda G, Yoshii T, Yamada T, Ono S, Shibasaki-Kurita T, Hosokawa S, Orime K, Hanaoka M, Sasaki H, Inazumi K, Yamada T, Kobayashi R, Ohki K, Haruhara K, Kobayashi Y, Yamanaka T, Terauchi Y, Tamura
    K. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Cardiovasc Diabetol. 2019 Aug 27;18(1):110. doi: 10.1186/s12933-019-0912-3. PubMed PMID: 31455298; PubMed Central PMCID: PMC6710883.

2018年

  1. Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab. 2018 May;20(5):1176-1185.
  2. Yamamoto M, Terauchi Y, Sakuda A, Takahashi M. Binder-free sheet-type all-solid-state batteries with enhanced rate capabilities and high energy densities. Sci Rep. 2018 Jan 19;8(1):1212.
  3. Sakamoto R, Yamakawa T, Takahashi K, Suzuki J, Shinoda MM, Sakamaki K, Danno H, Tsuchiya H, Waseda M, Takano T, Minagawa F, Takai M, Masutani T, Nagakura J, Shigematsu E, Ishikawa M, Nakajima S, Kadonosono K, Terauchi Y. Association of usual sleep quality and glycemic control in type 2 diabetes in Japanese: A cross sectional study. Sleep and Food Registry in Kanagawa (SOREKA). PLoS One. 2018 Jan 24;13(1):e0191771.
  4. Kimura M, Kondo Y, Aoki K, Shirakawa J, Kamiyama H, Kamiko K, Nakajima S, Terauchi Y. A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients With Type 2 Diabetes. J Clin Med Res. 2018 Mar;10(3):182-188.
  5. Ibuki A, Kuriyama S, Toyosaki Y, Aiba M, Hidaka M, Horie Y, Fujimoto C, Isami F, Shibata E, Terauchi Y, Akase T. Aging-like physiological changes in the skin of Japanese obese diabetic patients. SAGE Open Med. 2018 Feb 6;6:2050312118756662.
  6. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Serum adiponectin and insulin secretion: A direct or inverse association? J Diabetes Investig. 2018 Feb 16. doi: 10.1111/jdi.12821. [Epub ahead of print] PubMed PMID: 29451743.
  7. Yamada Y, Terauchi Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study. Adv Ther. 2018 Mar;35(3):367-381.
  8. Inoue H, Shirakawa J, Togashi Y, Tajima K, Okuyama T, Kyohara M, Tanaka Y, Orime K, Saisho Y, Yamada T, Shibue K, Kulkarni RN, Terauchi Y. Signaling between pancreatic β cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation. J Biol Chem. 2018 Apr 20;293(16):5934-5946.
  9. Kitao N, Nakamura A, Miyoshi H, Nomoto H, Takahashi K, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. The role of glucokinase and insulin receptor substrate-2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice. Metabolism. 2018 Mar 12. pii: S0026-0495(18)30082-9. doi: 10.1016/j.metabol.2018.03.010. [Epub ahead of print]
  10. Terauchi Y, Yamada Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T. Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study. J Diabetes Investig. 2018 Apr 1. doi: 10.1111/jdi.12846. [Epub ahead of print]
  11. Miya A, Nakamura A, Miyoshi H, Takano Y, Sunagoya K, Hayasaka K, Shimizu C, Terauchi Y, Atsumi T. Impact of Glucose Loading on Variations in CD4(+) and CD8(+) T Cells in Japanese Participants with or without Type 2 Diabetes. Front Endocrinol (Lausanne). 2018 Mar 20;9:81.
  12. Watada H, Shiramoto M, Irie S, Terauchi Y, Yamada Y, Shiosakai K, Myobatake Y, Taguchi T. G protein-coupled receptor 119 agonist DS-8500a effects on pancreatic β-cells in Japanese type 2 diabetes mellitus patients. J Diabetes Investig. 2018 Apr 6. doi: 10.1111/jdi.12849. [Epub ahead of print]
  13. Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care. 2018 Jun;41(6):1275-1284.
  14. Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kitao N, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. Sci Rep. 2018 May 1;8(1):6864.
  15. Terauchi Y, Riddle MC, Hirose T, Koyama M, Cheng X, Takahashi Y, Bolli GB. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use. Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414. [Epub ahead of print]
  16. Shirakawa J, Terauchi Y. SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. Ann Transl Med. 2018 Apr;6(7):129.
  17. Chiba Y, Yamakawa T, Tsuchiya H, Oba M, Suzuki D, Danno H, Takatsuka Y, Shigematsu H, Kaneshiro M, Terauchi Y. Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus. J Clin Med Res. 2018 Aug;10(8):648-656.
  18. Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care. 2018 Sep;41(9):e130-e132. 
  19.  Aoki K, Terauchi Y. Effect of Dehydroepiandrosterone (DHEA) on Diabetes Mellitus and Obesity. Vitam Horm. 2018;108:355-365.
  20. Osada UN, Terauchi Y. The new basal insulin analog glargine U-300 enables flexible injection schedule. Ann Transl Med. 2018 Nov;6(Suppl 1):S1.